医療従事者の為の最新医療ニュースや様々な情報・ツールを提供する医療総合サイト

Fortis Life Sciences Expands Its International Presence

2022年10月24日 PM09:00
このエントリーをはてなブックマークに追加


 

WALTHAM, Mass.

Fortis Life Sciences, a provider of high-quality reagents and custom services for discovery, development, and manufacturing, has expanded its international presence by opening an office in Seoul, South Korea.

South Korea’s pharmaceutical, diagnostic, and life science industry has grown to become one of the most comprehensive markets in Asia-Pacific, with increased demand from within and outside the region. Therefore, this strategic milestone is a significant development to bolster Fortis’ commitment to serving the Asian marketplace and increasing its personal connection with this customer base.

Fortis appointed Young K. Yun, PhD as APAC’s Vice President and General Manager. Dr. Yun will run the Fortis Korea headquarters in Seoul, Korea. Brian Kim, CEO of Fortis, remarked, “I am honored to announce that Young Yun is joining Fortis as Vice President and General Manager of APAC and establishing our regional HQ in Seoul, Korea. Young brings a wealth of regional and industry—both MNC and start-up—experience making him uniquely qualified for this important role.”

“With the expanded global demand and sophisticated supply chain in life science, diagnostic, and therapeutic markets, Fortis Life Sciences is answering scientists’ requests for faster turnaround time, the highest product quality, the best customer experience, and reliable scientific support,” said Dr. Yun. “We are excited to partner with leading diagnostic and life science companies in the region that have a proven track record of delivering the most innovative products to biomedical researchers and clinicians at a global level.”

About Fortis Life Sciences:

Fortis Life Sciences is a strategic platform company founded in 2020 with the mission to offer world-class products coupled with best-in-class customer experience. Over the course of two years, Fortis has built a portfolio of high-quality products and brands serving various life sciences end markets, including diagnostic, therapeutic, and research.

View source version on businesswire.com: https://www.businesswire.com/news/home/20221024005055/en/

CONTACT

Media Contact

Elizabeth Fretz

lfretz@fortislife.com

Related Posts Plugin for WordPress, Blogger...

同じカテゴリーの記事 

  • NRDL Inclusion Offers Substantial Opportunities for Innovative, Clinically Differentiated Therapies in China Despite Steep Price Reductions
  • ZCG关联公司收购Universal Marine Medical Supply International
  • エクセンシア、ESMO免疫腫瘍学会の年次総会でEXS-21546用の新規がん免疫療法バイオマーカーを発表
  • Takeda’s QDENGA®▼ (Dengue Tetravalent Vaccine [Live, Attenuated]) Approved for Use in European Union
  • 冠科生物宣布与ERS Genomics签订基因编辑专利CRISPR/Cas9的全球性许可协议